肾血流量作为常染色体显性多囊肾病疾病进展标志物
这项前瞻性队列研究纳入238例常染色体显性多囊肾病(ADPKD)成人和1421例健康对照,评估肾血流量(RBF)和滤过分数(FF)与疾病严重程度及进展的关联。结果显示ADPKD患者RBF显著降低,较高RBF与eGFR下降更慢、快速进展风险更低相关,且RBF加入Mayo影像分类可提高风险分层能力。
要点
- ADPKD患者各年龄段RBF均显著低于健康对照,即使eGFR相似的年轻患者也如此。
- 较高RBF与eGFR年下降更慢、快速进展风险更低及复合终点风险更低独立相关。
- RBF加入Mayo影像分类可将快速进展预测的AUC从0.69提升至0.79。
核心结论
- 降低的RBF是ADPKD早期标志,与疾病严重程度和肾功能下降相关,并可在MIC基础上改善风险分层。
研究设计与样本
- 前瞻性研究纳入238例ADPKD成人和1421例健康对照,来自Developing Intervention Strategies to Halt Progression of ADPKD观察性队列。
主要发现
- 横断面分析显示ADPKD患者各年龄段RBF均显著低于对照,即使eGFR与对照相似的年轻患者也如此。
- ADPKD患者中较低RBF与肾功能减低和肾脏体积增大相关。
- 随访5.6±3.5年期间,较高RBF(每SD)与eGFR年下降更慢相关(标准化β=0.34;95%CI 0.09-0.58;P=0.01)。
- 较高RBF与快速疾病进展(eGFR年下降≥3.0 ml/min per 1.73 m2) odds更低相关(OR=0.34;95%CI 0.17-0.70;P=0.003)。
- 较高RBF与复合终点(肾衰竭或eGFR下降≥30%)风险更低相关(HR=0.35;95%CI 0.20-0.60;P<0.001)。
关键数值与推荐
- 快速进展定义为eGFR年下降≥3.0 ml/min per 1.73 m2。
- 复合终点定义为肾衰竭或eGFR下降≥30%。
- RBF加入MIC后,预测快速进展的AUC从0.69(95%CI 0.60-0.76)提高至0.79(95%CI 0.72-0.85)。
临床怎么用
- RBF可作为ADPKD早期血流动力学标志物,辅助识别高风险患者并优化风险分层。
- 在Mayo影像分类基础上联合RBF可能提高对快速进展的预测能力。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Disease progression in autosomal dominant polycystic kidney disease (ADPKD) is variable. Renal blood flow (RBF) and filtration fraction (FF), reflecting hemodynamic alterations and hyperfiltration, may improve risk stratification. METHODS: This prospective study included 238 adults with ADPKD from the Developing Intervention Strategies to Halt Progression of ADPKD observational cohort study and 1421 healthy controls. Multivariable regression analyses assessed associations of RBF and FF with disease severity and progression. Kaplan-Meier analysis and classification performance metrics were used to evaluate clinical use beyond established risk stratification tools. RESULTS: Cross-sectionally, patients with ADPKD had significantly lower RBF compared with controls across all age groups, even in young patients with similar estimated glomerular filtration rate (eGFR) to controls. Within patients with ADPKD, lower RBF was associated with reduced kidney function and larger kidney volume. During follow-up of 5.6 ± 3.5 years, higher RBF (per SD) was associated with slower annual eGFR decline (standardized β = 0.34; 95% confidence interval [CI], 0.09-0.58; P = 0.01), lower odds of rapid disease progression (eGFR decline ≥ 3.0 ml/min per 1.73 m2/year) (odds ratio [OR] = 0.34; 95% CI, 0.17-0.70; P = 0.003) and lower composite-end point risk (kidney failure or ≥ 30% eGFR decline) (hazard ratio [HR] = 0.35; 95% CI, 0.20-0.60; P < 0.001). FF was significantly higher in patients aged 30-40 years, consistent with early hyperfiltration, but was not associated with disease progression. For the association with rapid progression, adding RBF to the Mayo Imaging Classification (MIC) increased the area under the curve (AUC) from 0.69 (95% CI, 0.60-0.76) to 0.79 (95% CI, 0.72-0.85). CONCLUSION: Reduced RBF is an early hallmark of ADPKD, associated with disease severity and kidney function decline, and improves risk stratification beyond MIC.
引用
- Wagenaar R, Mohamed AAA, Meijer E, et al. Renal Blood Flow as Marker for Disease Progression in ADPKD. Kidney Int Rep. 2026. PMID: 42926819. doi:10.1016/j.ekir.2026.107050
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。